A Phase 2 Study of Neoadjuvant Lenvatinib in Locally Advanced Invasive Thyroid Cancer
Latest Information Update: 07 Nov 2023
At a glance
- Drugs Lenvatinib (Primary)
- Indications Carcinoma; Thyroid cancer
- Focus Therapeutic Use
Most Recent Events
- 01 Nov 2023 Planned End Date changed from 1 Mar 2024 to 1 Mar 2025.
- 01 Nov 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Dec 2024.
- 06 Jun 2023 Trial design ,presented at the 59th Annual Meeting of the American Society of Clinical Oncology